T

op of the morning to you, and a fine one it is. Despite some overcast skies hovering this morning above the Pharmalot campus, our spirits remain as sunny as ever. And why not? As the Morning Mayor taught us: “Every brand new day should be unwrapped like a precious gift.” So as you tug on the ribbon, you can also catch up with some of the tidbits prepared for you. Hope your day is successful and, of course, do stay in touch …

The Food and Drug Administration suspended three clinical trials in which Merck was testing its Keytruda immunotherapy in combination with two Celgene medicines for blood cancer — Revlimid and Pomalyst — after more deaths were reported in patients receiving the Merck drug. Merck disclosed increased patient death rates last month and halted enrollment for new patients in two of the multiple myeloma studies.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi all, without going into the intracellular details, when are we going to learn that you cannot cure, predict, understand the complexity of living biology. Introducing a tablet to reduce generic symptoms is like ignoring debts that are posted through the door. Ok it seems like it keeps you from panicking but the problem is always there and it’s not getting any better. The human cells are so beyond our understanding that you could eat a pot of jam and find yourself cured from a particular disease because I believe that the truth behind cure is in the conscious brain.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.